Sun, Jan 25, 2015, 2:17 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

raysfrom98 493 posts  |  Last Activity: Jan 23, 2015 10:45 PM Member since: Mar 3, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • raysfrom98 raysfrom98 Jan 23, 2015 10:45 PM Flag

    Yes it is. And with likely revenue from Rindo in the not so distant future, short will be burnt toast.

  • raysfrom98 raysfrom98 Jan 23, 2015 4:09 PM Flag

    Have a great weekend my friend.

  • raysfrom98 raysfrom98 Jan 23, 2015 3:47 PM Flag

    I'm not sure, but I think Warren claimed to be Hispanic too. So she could run as well. If we run American Indians on both sides, she can still run.

  • raysfrom98 raysfrom98 Jan 23, 2015 2:42 PM Flag

    The Left and other peoples money, what a concept. They just can't understand, or don't want to understand how over taxation and over regulations very quickly diminish tax receipts, no matter the intent, or misguided good will. And to assume the good will of a socialist mind is a stretch. It's more about power, jealousy, and coveting.

    A healthy society will always have income/wealth disparity. As long as opportunity exist for all, all is good. People, families, and communities will always take advantage of glaring opportunity at different levels, some will never see the obvious opportunity, and yes some have more opportunity than others. And that should not be changed by government in most cases . It's just the way life is, and should be changed by the individual through his or her own efforts. And yes, there are many exceptions when promoting the general welfare, but there are tipping points that are often ignored, do too much and you do damage to society by removing incentive, do too little and responsibilities of government become derelict. It's a balancing act, societies that do it well, thrive, do it poorly, well we have many examples of that. Greece and Argentina come to mind as glaring examples of doing it wrong.

  • raysfrom98 raysfrom98 Jan 22, 2015 11:45 PM Flag

    • Reply•Share ›
    The below response to Senator Warren's money grab was so good, I felt no need to write my own. Enjoy.

    cocoon • 5 hours ago
    "It's hard to listen to this person who has never produced anything, run anything or make a payroll that the quality of the individual does matter or everyone would have a billion dollar drug up their sleeve.
    The idea that a successful company and drug need to be revenue generators for NIH is mind boggling when one is aware of all the costs associated with FDA approval, payroll taxes, corporate tax, municipal tax and state tax.
    The government has a clear revenue generator already when a successful drug is brought to market, why burden it more and take monies away from those who invested in it to fund another government entity? The risk is taken by individuals and shareholders, not the government. And yet, the government is guaranteed a profit with no risk to capital, business environment or political winds by taxing payrolls and profits.
    It is the company needs to say to government, "we built this, we risked our own monies, we support the communities,towns and states we are in and we have brought a tremendous product to assist other human beings."
    So get off our back, stop taking monies from us to support your ideals and let us invest this money to make more drugs and make more lives better. We, the company, have proven our ability to make people lives better.
    Lastly, I understand she is a millionaire. Maybe, like Bloomberg, she should start by parting with some of her own personal monies first.""

  • raysfrom98 raysfrom98 Jan 22, 2015 4:36 PM Flag

    Mymandon, considering how much emphasis was put on this small complement inhibitor study last time, I think it must be part of the SP factor this time as well. Though I must say, I was surprised how much emphasis was being put on this DDD trial and its potential larger ramifications.

  • raysfrom98 raysfrom98 Jan 22, 2015 3:47 PM Flag

    5 to 5, an even split? So if you disagree, please explain why. I want to understand your thinking.

  • raysfrom98 raysfrom98 Jan 22, 2015 12:25 PM Flag

    I think it depends on when they meet with the FDA, and how long that process takes. If it drags on past ASCO, expect a presentation there. If the FDA meets with Celldex on a fast pace, and considers Rindo for approval, we should see a press release at that time. I don't think they need to wait for the final event. Hopefully that event never takes place, God willing.

  • raysfrom98 raysfrom98 Jan 22, 2015 10:21 AM Flag

    BHO has been neutered for his last two years, so no worries on taxation issues. Unless the Republicans get stupid.

  • Reply to

    June will be interesting.

    by no25p Jan 21, 2015 11:15 PM
    raysfrom98 raysfrom98 Jan 22, 2015 12:31 AM Flag

    Whipper, thanks for the clarity.

  • Both Rindo's ReACT data, & TP10, (AKA CDX-1135) TP10 Use in Patients With C3 Glomerulopathy (C3G) are likely to alter the valuation of Celldex in June 2015, or shortly there after. I think we are seeing that happen now.

    Most of you already know the potential early approval of Rindo, due to the results of the p2 ReACT trial study and subsequent meetings with the FDA when possible early approval will be discussed.

    But what you may not know is, the TP10 trial for DDD, taking place at the University of Iowa, Started their recruiting efforts (5 patients needed) in November of 2014. AND, the time line for this study, (wait for it) 26 weeks in duration, "induction and maintenance periods combined". ""Maintenance dosing shall continue as described in Section 8.3.2, for a maximum of a 26-week treatment period (for the Induction and Maintenance Periods combined).""

    Now, assuming they have already identified the five patients, and considering the difficulty in doing so last time, I would assume Celldex did not agree to let this study go forth without some assurances the university has located the 5 subjects, assuming all these scenarios, this trial in DDD could have data to report as early as May or June of THIS YEAR.

    So put these two possibilities together for mid 2015 and I suspect we are seeing those in the know Covering there positions.

    Short if you will, but do it at greater and greater risk in 2015.

    My question is, why has Celldex management not put out a press release on this TP10/CDX-1135 trial, that started in November 2014. I assume they want to see the University perform well, before they broadcast the effort for a second time.

  • Reply to

    June will be interesting.

    by no25p Jan 21, 2015 11:15 PM
    raysfrom98 raysfrom98 Jan 21, 2015 11:50 PM Flag

    Wow, are you really that much of a leftist ideologue?

  • Reply to

    From todays article !!

    by wiszad Jan 21, 2015 4:52 PM
    raysfrom98 raysfrom98 Jan 21, 2015 10:41 PM Flag

    no25p, both sides have been correct with Celldex over time. We can't know how it is going to go in the short term, so you better lean on the science and the management to determine your course of action.
    We are only here for the ride, we (the small investor) are not driving.

    There are a bunch of moving parts with Celldex these days, you might want to stake a long position and keep it, while at the same time working your trading shares in the peaks and valleys.

  • Reply to

    From todays article !!

    by wiszad Jan 21, 2015 4:52 PM
    raysfrom98 raysfrom98 Jan 21, 2015 8:16 PM Flag

    Yes sir, that's how it works.

  • Reply to

    Anyone need a good job?

    by raysfrom98 Jan 21, 2015 8:09 PM
    raysfrom98 raysfrom98 Jan 21, 2015 8:14 PM Flag

    I will put in a good word.

  • Reply to

    Anyone need a good job?

    by raysfrom98 Jan 21, 2015 8:09 PM
    raysfrom98 raysfrom98 Jan 21, 2015 8:11 PM Flag

    Individual responsibilities include:

    Works Strategically with regard to the following:
    o Training content.
    o Training Platform/Levers.
    o Budget Management.
    o Learning Management Systems.
    o Launch training vs ongoing training.
    o Content based training vs. skills based training.
    The Development of New Hire and Launch curriculum for field team.
    Train on Product/Disease State and Access/Reimbursement.
    Management of Training Agency/Vendor in creation of content.
    Select/Manage LMS Vendor and oversee LMS installation, maintenance and utilization.
    The Development of new hire training resources.
    Develop and execute advanced level training/ongoing training continuum.
    Lead and oversee the development and execution of live and remote training for all field-based employees (including Account Executives – in collaboration with market access team).
    Coordinate, oversee, and execute the Launch meetings.
    Conduct in-field coaching as appropriate to augment manager efforts.
    Guide Materials and Initiatives through legal/medical/regulatory review process.
    Ensure training outcomes are identified, measured, and used to facilitate a top-tier continuous improvement process.
    Required Skills:

    Excellent project management skills.
    Strong Presentation Skills.
    Flexibility and ability to adapt to changing market conditions.
    Excellent communication skills.
    Ability to work with a team and individually.

  • raysfrom98 by raysfrom98 Jan 21, 2015 8:09 PM Flag

    Bio/Pharm Sales Training & Development, Senior Manager (Hampton, NJ)

    Overview:

    We are looking for a person to fill the Bio/Pharm Sales Training & Development position in our Hampton, NJ facility. The Senior Manager be responsible for leading the development and execution of training content for field based teams, ensuring that all training is consistent with commercial strategy. They will create training/development strategies and content that proactively and directly impact the successful global launches of late stage Celldex compounds.
    The Senior Manager will be also be charged with establishing the Training/Development system for Celldex, as well as developing the launch and ongoing training for the company’s inaugural product. This position will demand a large degree of cross-functional cooperation with matrix-team members including but not limited to marketing (commercial and payer), medical affairs, clinical science, market research, market access/reimbursement, and legal/regulatory/medical content review teams.

  • Reply to

    Volume Question

    by mjacob56 Jan 21, 2015 7:11 PM
    raysfrom98 raysfrom98 Jan 21, 2015 7:58 PM Flag

    MJ, about your question.

    "Could large holders be artificially inflating the price and getting out of their long position based on something that they know that we don't? "

    Let me rephrase your question.

    Could large holders have be artificially deflating the price over the last year and getting into larger long position based on something that they know that we don't?

  • raysfrom98 raysfrom98 Jan 21, 2015 3:07 PM Flag

    No, but it makes for a great story while we wait for the next game.

CLDX
22.75+0.4000(+1.79%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.